News | October 23, 2007

Isosmolar Visipaque Demonstrates Low Incidence of Contrast-Induced Nephropathy

October 24, 2007 — Study results presented this week at the Transcatheter Cardiovascular Therapeutic (TCT) annual meeting in Washington D.C., demonstrated that the use of GE's isosmolar contrast medium Visipaque (iodixanol) resulted in a statistically significantly lower rate of contrast-induced nephropathy (CIN) than the low osmolar nonionic contrast agent ioversol, according to the company.
The study was conducted in 250 patients with diabetes who underwent either coronary angiography to determine if there was disease in the arteries, or percutaneous coronary intervention to improve circulation of diseased arteries that supply blood to the heart muscle.
The authors reported the use of the isosmolar contrast medium Visipaque resulted in a statistically significantly lower rate of CIN at 72 hours following contrast medium administration when compared with the low osmolar nonionic contrast agent ioversol (2.5% vs 8.3%; p = 0.047).
Study investigators also noted that in the group of patients at highest risk, those who underwent a percutaneous coronary intervention procedure and received higher amounts of a contrast medium, Visipaque use also resulted in significantly lower rate of CIN at 72 hours than ioversol (2% vs 13.5%; p = 0.02).

For more information: www.gehealthcare.com

Related Content

ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
contrast media
Feature | Contrast Media Injectors | March 02, 2017 | By Jeff Zagoudis
With medical imaging use on the rise, contrast media use is expected to grow as well, according to a May 2016 report...
contrast media
News | Contrast Media | December 09, 2016
At the 2016 Annual Meeting of the Radiological Society of North America (RSNA 2016), Bracco Diagnostics Inc. showcased...
GlobalData, contrast media injectors market,
News | Contrast Media Injectors | May 03, 2016
The global market for contrast media injectors is set to increase from $830 million in 2015 to almost $1.8 billion by...
CTA, CT, contrast media injector, contrast injector, EmpowerCTA

Bracco's new EmpowerCTA+, designed for cardiac CT angiography exams.

Feature | Contrast Media Injectors | April 29, 2016 | Jeff Zagoudis
The biggest trend in contrast media injector technology today is one seen throughout all of healthcare — doing more...
Guerbet, OptiOne single-head contrast delivery system, FDA 510k clearance
Technology | Contrast Media Injectors | February 16, 2016
February 16, 2016 — Guerbet announced that it has received 510K clearance from the U.S.
News | Contrast Media | November 29, 2015
November 29, 2015 — Guerbet announced that it has completed its acquisition of the "contrast media and delivery syste
Galt Medical, Health Line International Corp., Nexus CT Midline Catheter with MST Insertion Kit

Image courtesy of Galt Medical

Technology | Contrast Media Injectors | October 01, 2015
October 1, 2015 — Galt Medical has partnered with Health Line International Corp.
Technology | March 06, 2015
Bracco Imaging, through its business unit Bracco Injeneering SA, announced the availability of its EmpowerCTA+, an...
Overlay Init